Compare ADTN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | SPRY |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.4M | 634.5M |
| IPO Year | 1996 | 2020 |
| Metric | ADTN | SPRY |
|---|---|---|
| Price | $7.27 | $5.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $15.50 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,083,807,000.00 | $84,278,000.00 |
| Revenue This Year | $11.09 | $87.40 |
| Revenue Next Year | $8.47 | $81.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.46 | N/A |
| 52 Week Low | $7.11 | $4.91 |
| 52 Week High | $19.98 | $13.15 |
| Indicator | ADTN | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 46.35 |
| Support Level | $7.43 | $5.04 |
| Resistance Level | $8.81 | $6.58 |
| Average True Range (ATR) | 0.29 | 0.35 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 5.01 | 47.10 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.